DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/smv8q8/ganaxolone) has announced the addition of GlobalData's new report "Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022" to their offering.
PharmaPoint Drug Evaluation report, Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.
Ganaxolone is a first-in-class synthetic neurosteroid analog of the endogenous neurosteroid allopregnanolone. It has novel GABA-A receptor modulation and unique broad-spectrum protective efficacy, and is under development for the treatment of uncontrolled partial-onset seizures and infantile spasms. Marinus Pharmaceuticals licensed ganaxolone from Purdue Pharma and is currently conducting late-stage Phase II trials for ganaxolone as an adjunctive therapy in adult patients with refractory partial seizures and in children with infantile spasms. Ganaxolone has been administered to more than 900 healthy adult volunteers and patients in Phase I and Phase II studies, and was shown to be well tolerated and safe in adults, children, and infants (Marinus Pharmaceuticals, 2012).
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Disease Management
5 Competitive Assessment